SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phasening phase followed by a stabilization phase

Mount Sinai Expands Center for Post-COVID Care to Serve Patients in East Harlem and South Bronx

Study finds long-lasting antibodies after COVID-19 vaccine

Long-Term Data Reveals SARS-CoV-2 Infection and Vaccine-Induced Antibody Responses Are Long-Lasting

Mount Sinai Receives $2.6 Million Grant From PolyBio Research Foundation for Long COVID Clinical Trials

CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing

People with Long COVID Have Distinct Hormonal and Immune Differences From Those Without This Condition

UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination

Mount Sinai Receives $6.2 Million Grant from the Steven & Alexandra Cohen Foundation for the Clinical Care of Long Lyme Disease

Mount Sinai Receives NIH Grant to Develop Vaccines That Can Protect Against Many Different Types of Coronaviruses

Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission